# Radiation Therapy for Prostate Cancer
## Overview
Radiation therapy for prostate cancer encompasses several modalities, including external beam radiation, brachytherapy, stereotactic body radiation therapy (SBRT), and combined androgen deprivation therapy (ADT). Each approach has distinct toxicity profiles and long-term functional outcomes that are often compared with surgical treatment. Understanding these differences is crucial for tailoring therapy to individual patient risk and preferences.
---
## External Beam Radiation Therapy (EBRT)
### Intensity-Modulated Radiation Therapy (IMRT)
IMRT is the current standard technique for delivering EBRT. It uses computer-optimized beam profiles to conform the radiation dose precisely to the prostate target while minimizing exposure to adjacent organs such as the rectum and bladder. Dose escalation to 78-81 Gy has been shown to improve biochemical control compared to conventional doses around 70 Gy. Treatment is typically delivered daily over 7 to 9 weeks using conventional fractionation, with doses of 1.8 to 2.0 Gy per fraction.
### Volumetric Modulated Arc Therapy (VMAT)
VMAT is a variant of IMRT that employs a rotating gantry to deliver radiation more rapidly. It achieves equivalent dosimetric outcomes to IMRT but improves treatment efficiency by shortening delivery times.
### Image-Guided Radiation Therapy (IGRT)
IGRT involves daily imaging techniques such as cone-beam CT, fiducial markers, or electromagnetic transponders to verify the prostate’s position before each treatment. This approach corrects for day-to-day organ motion, allowing for tighter treatment margins and reduced toxicity. The use of SpaceOAR hydrogel, a rectal spacer injected between the prostate and rectum, further reduces rectal radiation dose and associated toxicity.
### Hypofractionation
Hypofractionation refers to delivering higher doses per fraction over fewer sessions. Moderate hypofractionation, such as 60 Gy in 20 fractions (3 Gy per fraction) over 4 weeks, has been validated by trials including RTOG 0415, PROFIT, and CHHiP as non-inferior to conventional fractionation. It is now widely adopted as a standard option. Ultra-hypofractionation or SBRT delivers 35-40 Gy in 5 fractions (7-8 Gy per fraction) over 1 to 2 weeks. Trials like HYPO-RT-PC and PACE-B have demonstrated non-inferiority of SBRT compared to conventional fractionation for low- and intermediate-risk patients. SBRT is delivered via CyberKnife or linear accelerator platforms, offering patient convenience and potential cost savings. However, longer follow-up is needed before widespread adoption in high-risk disease.
### Proton Beam Therapy
Proton beam therapy uses protons instead of photons, exploiting the Bragg peak phenomenon to deposit radiation dose at a specific depth with rapid falloff beyond the target. This theoretically reduces exit dose to surrounding tissues. Despite this advantage, there is no Level 1 evidence demonstrating clinical superiority over photon-based IMRT for prostate cancer. Proton therapy is significantly more expensive and less widely available. Ongoing trials are comparing outcomes between proton and photon therapies.
---
## Brachytherapy
### Low-Dose-Rate (LDR) Brachytherapy
LDR brachytherapy involves permanent implantation of radioactive seeds, typically iodine-125 or palladium-103, into the prostate via transperineal ultrasound-guided placement. It is used as monotherapy for low- and favorable intermediate-risk prostate cancer. The prescribed dose is 145 Gy for iodine-125 or 125 Gy for palladium-103. LDR brachytherapy achieves excellent long-term outcomes, with 10-year biochemical recurrence-free survival exceeding 90% in low-risk patients. Contraindications include large prostate volume (greater than 60 cc, although this can sometimes be reduced with ADT), prior transurethral resection of the prostate (TURP) due to increased risk of incontinence, and significant baseline lower urinary tract symptoms.
### High-Dose-Rate (HDR) Brachytherapy
HDR brachytherapy uses temporary afterloading of an iridium-192 source delivered through transperineal catheters placed under anesthesia. After treatment, the catheters are removed. HDR is commonly used as a boost in combination with EBRT for intermediate- and high-risk disease, but it can also be used as monotherapy in select cases with 2 to 3 fractions. The main advantage of HDR brachytherapy is the ability to optimize the dose precisely after implant placement.
### Combination: EBRT + Brachytherapy Boost
The ASCENDE-RT trial demonstrated that combining EBRT with an LDR brachytherapy boost provides superior biochemical control compared to EBRT with dose-escalated EBRT boost in intermediate- and high-risk patients. However, this approach is associated with higher genitourinary toxicity and is therefore generally reserved for patients with intermediate to high-risk disease.
---
## Androgen Deprivation Therapy (ADT) with Radiation
### Rationale
ADT enhances the effectiveness of radiation by sensitizing prostate cancer cells, reducing prostate volume to improve dosimetry, and treating micrometastatic disease.
### Duration by Risk Group
ADT is not indicated for low-risk patients receiving radiation. For favorable intermediate-risk patients, 4 to 6 months of ADT (neoadjuvant plus concurrent) is recommended. The same duration applies to unfavorable intermediate-risk patients. High-risk patients require long-term ADT lasting 18 to 36 months, including neoadjuvant, concurrent, and adjuvant phases. Trials such as DART 01/05 and EORTC 22961 have shown that long-term ADT (2 to 3 years) is superior to short-term ADT (6 months) in this group.
| Risk Group | ADT Duration | Radiation Approach |
|---|---|---|
| Low | None | LDR brachytherapy or dose-escalated EBRT |
| Favorable Intermediate | 4-6 months | EBRT (conventional or hypofractionated) +/- brachy boost |
| Unfavorable Intermediate | 4-6 months | EBRT +/- brachytherapy boost |
| High | 18-36 months | EBRT + brachy boost; consider pelvic LN RT |
| Very High / Node-Positive | 24-36 months | EBRT + long-term ADT; intensified systemic therapy |
### ADT Agents
LHRH agonists like leuprolide and goserelin cause an initial testosterone flare, which is mitigated by administering antiandrogens for 2 to 4 weeks. LHRH antagonists such as degarelix and relugolix do not cause flare and achieve faster castration. Relugolix, an oral agent, has demonstrated a lower cardiovascular event rate compared to leuprolide in the HERO trial. Antiandrogens like bicalutamide are used either for flare protection or as part of combined androgen blockade.
---
## Radiation by Risk Group
### Low Risk (Grade Group 1, PSA <10, T1-T2a)
For low-risk patients, active surveillance is preferred for most. Radiation options include LDR brachytherapy monotherapy or dose-escalated EBRT, without ADT. Outcomes are excellent, with 10-year biochemical recurrence-free survival exceeding 90%.
### Favorable Intermediate Risk
Treatment options include EBRT (either conventional or hypofractionated) combined with short-term ADT for 4 to 6 months. Alternatively, LDR brachytherapy monotherapy may be considered in select cases, or EBRT combined with a brachytherapy boost without ADT.
### Unfavorable Intermediate Risk
These patients typically receive EBRT plus short-term ADT for 4 to 6 months. EBRT combined with a brachytherapy boost is also considered. SBRT is currently under investigation for this risk group.
### High Risk
High-risk patients are treated with EBRT plus long-term ADT for 18 to 36 months. EBRT combined with a brachytherapy boost is supported by ASCENDE-RT data. Pelvic lymph node irradiation is controversial but commonly included. The STAMPEDE trial’s arm H demonstrated that adding abiraterone to ADT and radiation improves failure-free survival.
### Very High Risk / Node-Positive
Radiation combined with long-term ADT (2 to 3 years) is standard. The STAMPEDE trial showed that radiation to the primary tumor in low-volume metastatic disease improves overall survival. Intensified systemic therapies such as abiraterone and docetaxel are under study in combination with radiation.
---
## Post-Prostatectomy Radiation
### Adjuvant Radiation
Adjuvant radiation is delivered within 4 to 6 months after radical prostatectomy for adverse pathological features, including positive surgical margins, extraprostatic extension (pT3a), or seminal vesicle invasion (pT3b). The typical dose is 64 to 72 Gy to the prostatic fossa. The SWOG 8794 trial demonstrated improved metastasis-free survival with adjuvant radiation in patients with pT3 disease or positive margins.
### Salvage Radiation
Salvage radiation is administered at the time of biochemical recurrence, indicated by rising PSA after prostatectomy. It is most effective when PSA is less than 0.5 ng/mL, ideally below 0.2 ng/mL. Trials such as RAVES, RADICALS-RT, and GETUG-17 have shown that early salvage radiation is non-inferior to adjuvant radiation, allowing many patients to avoid overtreatment. The current trend favors early salvage radiation over routine adjuvant therapy. Adding short-term ADT to salvage radiation improves outcomes, as demonstrated in GETUG-16 and RTOG 9601.
---
## Toxicity
### Acute (During and Within 3 Months)
Acute genitourinary toxicity includes dysuria, frequency, and urgency, affecting 40 to 60% of patients. Gastrointestinal side effects such as diarrhea, tenesmus, and rectal urgency occur in 30 to 40%. Fatigue is also common. These symptoms are generally self-limiting and managed with alpha-blockers and anti-diarrheal agents.
### Late (>3 Months)
Late genitourinary toxicity includes urinary frequency and urgency in 10 to 20% of patients, hematuria in 3 to 5%, urethral stricture in 2 to 5%, and incontinence in fewer than 5%. Late gastrointestinal toxicity manifests as rectal bleeding or proctitis in 5 to 10%, chronic diarrhea in 5%, and rectal fistula in less than 1%. Erectile dysfunction develops gradually in 30 to 50% of patients by 5 years, differing from the immediate onset seen after surgery. There is a small increased risk of secondary malignancies, such as bladder and rectal cancer, with a latency period exceeding 5 years after pelvic radiation.
### Risk Mitigation
The use of SpaceOAR hydrogel reduces rectal V70 radiation dose by 75%, significantly decreasing rectal toxicity. Dose constraints aim to keep rectal wall V70 below 15% and bladder V70 below 25%. IGRT and IMRT optimization further minimize toxicity.
---
## Surgery vs. Radiation: Comparative Outcomes
The ProtecT trial with 15-year follow-up found similar cancer-specific mortality (~3%) across active monitoring, surgery, and radiation arms. Metastasis rates were slightly higher with active monitoring but similar between surgery and radiation. Functionally, surgery results in more incontinence, whereas radiation causes more bowel symptoms. Erectile dysfunction rates converge over time between the two modalities.
Functionally, surgery causes immediate erectile dysfunction and early urinary incontinence, with potential recovery over 12 to 24 months. Radiation leads to a gradual onset of erectile dysfunction over years, with lower initial incontinence but potential bowel toxicity. Patient preference and comorbidities are key factors guiding treatment choice.
A comparative diagram of radiation therapy modalities for prostate cancer: IMRT/VMAT, SBRT, LDR brachytherapy (permanent seeds), and HDR brachytherapy (temporary catheters). Each modality is illustrated with a simplified cross-sectional view of the prostate showing beam angles or seed/catheter placement, along with typical dose/fractionation schedules, treatment duration, and indications by risk group. Professional radiation oncology educational illustration style.
A treatment algorithm flowchart for prostate cancer radiation therapy organized by NCCN risk group (low, favorable intermediate, unfavorable intermediate, high, very high). Each risk category branches to recommended radiation modality (EBRT, brachytherapy, combination), ADT duration (none, 4-6 months, 18-36 months), and consideration for pelvic lymph node irradiation. Key clinical trial data informing each recommendation is annotated. Clean clinical algorithm format.
A timeline comparison of functional outcomes (continence, erectile function, and bowel function) after radical prostatectomy vs. radiation therapy over 5 years. Three paired line graphs showing percentage of patients with normal function at baseline, 6 months, 1 year, 2 years, and 5 years for each modality. Demonstrates the immediate impact and gradual recovery pattern for surgery vs. the delayed decline pattern for radiation. Data derived from ProtecT and CEASAR studies. Publication-quality line graph format.
---
## Clinical Pearls
Dose escalation to 78-81 Gy is essential for EBRT, as lower doses result in inferior biochemical control. Moderate hypofractionation, delivering treatment in 20 fractions over 4 weeks, is now standard and equivalent to conventional fractionation, reducing the treatment burden. SBRT, consisting of 5 fractions, is gaining acceptance for low- and intermediate-risk patients, though longer follow-up is needed before widespread use in high-risk disease. Long-term ADT lasting 2 to 3 years is critical for high-risk prostate cancer patients receiving radiation; omitting or shortening ADT compromises survival. Early salvage radiation, initiated when PSA is between 0.2 and 0.5 ng/mL, is preferred over routine adjuvant radiation after prostatectomy, as it avoids overtreatment while maintaining oncologic outcomes. The SpaceOAR hydrogel significantly reduces rectal toxicity and should be considered for all patients undergoing EBRT. Radiation-induced erectile dysfunction develops gradually and progressively, unlike the immediate onset seen after surgery, so patients should be counseled that erectile function may decline over several years even if initially preserved.
---
## References
- Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT). N Engl J Med. 2023;388(17):1547-1558
- Dearnaley D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer (CHHiP). Lancet Oncol. 2016;17(8):1047-1060
- Widmark A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC). Lancet. 2019;394(10196):385-395
- Rodda S, et al. ASCENDE-RT: LDR brachytherapy boost vs. EBRT dose-escalation for intermediate- and high-risk prostate cancer. J Clin Oncol. 2017;35(18):1978-1986
- Parker CC, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT). Lancet. 2020;396(10260):1413-1421
- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 4.2024